Merck + Co., Inc.

Merck Sharp + Dohme Corp.

Methylgene, Inc.

Kevin D Dykstra

Frank P DiNinno

Jared N Cumming

Wen-Lian Wu

Milton L Hammond

Hong Liu

Shawn P Walsh

Derun Li

Alan W Hruza

Brandon Mitsuo Taoka

Haiqun Tang

Andreas Verras

Andrew William Stamford

Ronald W Ratcliffe

Brian Alexander McKittrick

Kun Liu

Michael W Miller

Dong-Ming Shen

Steven L Colletti

Soumya P Sahoo

Arkadii Vaisburg

James V Heck

Duane E DeMong

Helen Y Chen

Peter T Meinke

Ashwin Umesh Rao

John P Caldwell

Timothy A Blizzard

Jayaram R Tagat

Hiroo Koyama

Stephane Raeppel

Michael Mannion

Meng-Hsin Chen

Jubrail Rahil

Katherine Young

Zhiyong Hu

Frederic Gaudette

Mary Ann Caplen

Claire Lankin

John Qiang Tan

Jeffrey Donald Hermes

Qiang Tan

Timothy A Cernak

Seongkon Kim

Ginger Xu-Qiang Yang

Nancy Z Zhou

Nafsika Georgopapadakou

Tianyuan Zhang

Amy McCracken

Stephen J O'Keefe

Frank Dininno

Amy Mccracken

Brian Mckittrick

Thimothy A Cernak

Stephen J O'KEEFE

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia Formula (I). 

Antidiabetic bicyclic compounds

Described herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as Cyp8b1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for diabetes and cardiovascular disease. 

Compound useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolc disease

Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as Cyp8b1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for diabetes and cardiovascular disease.

Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease

The present invention is directed to compounds of the Formula I: as well as pharmaceutically acceptable salts thereof, that may be useful for treating aldosterone-mediated diseases. The invention furthermore relates to specific diastereomers and enantiomers of the compounds, to processes for preparing compounds of the Formula I, to their potential use for the therapy and prophylaxis of the above-mentioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the Formula I. 

Mineralocorticoid receptor antagonists

This invention provides novel &#x3b2;-lactamase inhibitors of the aryl- and heteroaryl-sulfonamidomethylphosphonate monoester class having nitrogen-based cations or quarternary ammomium groups. The compounds inhibit three classes of &#x3b2;-lactamases and synergize the antibacterial effects of &#x3b2;-lactam antibiotics (e.g., imipenem and ceftazimdime) against those micro-organisms normally resistant to the &#x3b2;-lactam antibiotics as a result of the presence of the &#x3b2;-lactamases.

Inhibitors of beta-lactamase

Compounds described by the chemical formula (I) or pharmaceutically acceptable salts thereof: are inhibitors of p38 and are useful in the treatment of inflammation such as in the treatment of asthma, COPD, ARDS, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; inflamed joints, eczema, psoriasis or other inflammatory skin conditions such as sunburn; inflammatory eye conditions including conjunctivitis; pyresis, pain and other conditions associated with inflammation.

P38 kinase inhibiting agents

Carbapenem antibacterial compounds, compositions containing such compounds and methods of treatment

Halophenoxy substituted carbapenem antibacterial compounds

The present invention relates to carbapenem antibacterial agents in which the carbapenem nucleus is substituted at the 2-position with an iodo-substituted phenyl linked through a CH,&mdash;O&mdash; group. The compounds of the invention are represented by formula I:

The present invention relates to carbapenem antibacterial agents in which the carbapenem nucleus is substituted at the 2-position with a naphthosultam linked through a --Z--CH.sub.2 group. The naphthosultam is further substituted with various substituent groups including cationic groups. The compounds are represented by formula I: ##STR1## Pharmaceutical compositions and methods of use are also included.

Carbapenem antibacterial compounds, compositions containing such

Carbapenems of the formula ##STR1## are useful antibacterial agents.

2-biphenyl-carbapenem antibacterial agents

Growing community of inventors

West Milford, NJ, United States of America

Kevin D Dykstra